Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.53 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28020837 | 0.90 | SIGMAR1 (0.58) | ABCB1ABCG2SIGMAR1GRIN2BKCNJ1 | |
| SCHEMBL6296037 | 0.87 | DRD4 (0.54) | SIGMAR1GRIN2BGRIN1 | |
| SCHEMBL7598211 | 0.86 | ABCB1 (0.74) | ABCB1ABCG2SIGMAR1KCNJ1KCNH2 | |
| Water SCHEMBL10361432 | 0.83 | KCNJ1 (0.68) | ABCB1ABCG2SIGMAR1KCNJ1KCNH2 | |
| Water SCHEMBL10361433 | 0.83 | KCNJ1 (0.68) | ABCB1ABCG2SIGMAR1KCNJ1KCNH2 | |
| SCHEMBL6493156 | 0.82 | GRIN1 (0.49) | ABCB1ABCG2GRIN2BGRIN1 | |
| SCHEMBL6291722 | 0.82 | GRIN2B (0.55) | GRIN2BGRIN1 | |
| SCHEMBL21412698 | 0.82 | SIGMAR1 (0.52) | SIGMAR1GRIN2BGRIN1HRH3 | |
| Hydrochloric Acid SCHEMBL8186681 | 0.81 | GRIN2B (0.54) | SIGMAR1GRIN2BGRIN1 | |
| SCHEMBL8790326 | 0.80 | KCNJ1 (0.67) | ABCB1ABCG2KCNJ1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | ABCB1 699/4885ABCG2 436/4885SIGMAR1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.